Jeff Yass’s Provention Bio, Inc. Common Stock PRVB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-444,000
| Closed | -$10.7M | – | 13716 |
|
|
2023
Q1 | $10.7M | Buy |
444,000
+316,600
| +249% | +$3.97M | ﹤0.01% | 2352 |
|
|
2022
Q4 | $1.35M | Buy |
127,400
+35,600
| +39% | +$287K | ﹤0.01% | 5521 |
|
|
2022
Q3 | $413K | Buy |
91,800
+47,000
| +105% | +$214K | ﹤0.01% | 8982 |
|
|
2022
Q2 | $179K | Sell |
44,800
-30,900
| -41% | -$146K | ﹤0.01% | 10806 |
|
|
2022
Q1 | $554K | Buy |
75,700
+600
| +0.8% | +$3.59K | ﹤0.01% | 8718 |
|
|
2021
Q4 | $422K | Sell |
75,100
-26,300
| -26% | -$167K | ﹤0.01% | 9622 |
|
|
2021
Q3 | $649K | Sell |
101,400
-69,300
| -41% | -$445K | ﹤0.01% | 8717 |
|
|
2021
Q2 | $1.44M | Buy |
170,700
+57,100
| +50% | +$461K | ﹤0.01% | 6764 |
|
|
2021
Q1 | $1.19M | Buy |
113,600
+44,800
| +65% | +$630K | ﹤0.01% | 7255 |
|
|
2020
Q4 | $1.17M | Hold |
68,800
| – | – | ﹤0.01% | 6363 |
|
|
2020
Q3 | $883K | Sell |
68,800
-1,000
| -1% | -$12.6K | ﹤0.01% | 6422 |
|
|
2020
Q2 | $985K | Buy |
69,800
+19,100
| +38% | +$241K | ﹤0.01% | 5960 |
|
|
2020
Q1 | $466K | Sell |
50,700
-26,400
| -34% | -$340K | ﹤0.01% | 7098 |
|
|
2019
Q4 | $1.15M | Buy |
77,100
+27,800
| +56% | +$248K | ﹤0.01% | 5262 |
|
|
2019
Q3 | $336K | Buy |
+49,300
| New | +$499K | ﹤0.01% | 8055 |
|
Other funds holding PRVB
Jeff Yass's PRVB Position: Q2 2023 in Review
Jeff Yass sold out of Provention Bio, Inc. Common Stock (PRVB) in Q2 2023, closing a stake of 363,758 shares — an estimated $8.77M sold.
Jeff Yass first reported a position in PRVB in Q2 2019 and held it in 16 quarters. The position peaked at $8.77M in Q1 2023. 1 fund tracked by Wall St. Rank holds PRVB as of Q2 2023.
- Jeff Yass reported no remaining Provention Bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- Jeff Yass sold 363,758 Provention Bio, Inc. Common Stock shares in Q2 2023, an estimated $8.77M.
- Jeff Yass first reported a position in Provention Bio, Inc. Common Stock in Q2 2019 and held it in 16 quarters.
- Jeff Yass's Provention Bio, Inc. Common Stock position peaked at $8.77M in Q1 2023.
- 1 fund tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q2 2023.
Based on Susquehanna International Group's 13F filing for Q2 2023, filed 11 Aug 2023.